Details for New Drug Application (NDA): 218160
✉ Email this page to a colleague
The generic ingredient in RETEVMO is selpercatinib. One supplier is listed for this compound. Additional details are available on the selpercatinib profile page.
Summary for 218160
Tradename: | RETEVMO |
Applicant: | Loxo Oncol Eli Lilly |
Ingredient: | selpercatinib |
Patents: | 3 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 218160
Generic Entry Date for 218160*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 218160
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
RETEVMO | selpercatinib | TABLET;ORAL | 218160 | NDA | Eli Lilly and Company | 0002-5340 | 0002-5340-60 | 60 TABLET, COATED in 1 BOTTLE (0002-5340-60) |
RETEVMO | selpercatinib | TABLET;ORAL | 218160 | NDA | Eli Lilly and Company | 0002-5562 | 0002-5562-60 | 60 TABLET, COATED in 1 BOTTLE (0002-5562-60) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 40MG | ||||
Approval Date: | Apr 10, 2024 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | May 8, 2025 | ||||||||
Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
Patent: | ⤷ Subscribe | Patent Expiration: | Oct 10, 2037 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Patent: | ⤷ Subscribe | Patent Expiration: | Oct 10, 2037 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAS PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS |
Complete Access Available with Subscription